We therefore believe that the words "barren end" in Taubes' article do not quite fit the case.

Tsunenori Sakamoto

Director, Electron Devices Division, Electrotechnical Laboratory, 1-1-4 Umezono, Tsukuba, Ibaraki, 305, Japan

#### Saving Old-Growth Forests


I would like to clarify my comments regarding forests of eastern Oregon and Washington as quoted in the Science-Scope item "Can logging save old-growth forests" (1 Oct., p. 19). Health problems in these forests do not stem from too little logging, but rather from too much logging of the wrong kind, a situation that has been exacerbated by excluding natural wildfires. Some judicious and highly selective logging would probably benefit forest health in the short-run; however, the members of the Eastside Forests Scientific Society Panel, along with other scientists in this region, believe that a long-term solution lies not in more logging, but in restoring the forested landscape of the region to at least some reasonable approximation of what it was before logging. Restoring the landscape of this region to one that is more resistant and resilient to natural disturbances is a critically important component of protecting the few remaining oldgrowth stands and old-growth associated species. Reducing tree stocking by logging some small trees and reintroducing the natural fire regime are ways to accomplish this while protecting and restoring the habitat and natural processes.

David A. Perry

Eastside Forests Scientific Society Panel, and Department of Forest Sciences, Oregon State University, Corvallis, OR 97331–7501

#### **Corrections and Clarifications**

The ScienceScope item "NIH shakeup continues" (29 Oct., p. 643) incorrectly described the position of Francis Collins, director of the National Center for Human Genome Research, on the National Institutes of Health's (NIH's) decision 2 years ago to file for patents on gene fragments of unknown function. Collins does not believe it was appropriate for NIH to file for the patents in the first place, but since the applications have been filed, he now believes they should be pursued to a conclusion in order to clarify whether such gene fragments are patentable.




## A new cGK Inhibitor: Rp-8-pCPT-cGMPS!

The R-isomer of 8- (4-chlorophenylthio) guanosine - 3', 5' - cyclic monophosphorothioate (Rp-8-pCPT-cGMPS) blocks the signal transduction of the "second messenger" cyclic GMP by inhibition of cGMP-dependent protein kinase (cGK) type  $|\alpha\rangle$ . It is a novel and unique tool to prove a probable involvement of cyclic GMP in the biological system of interest. Developed by BIOLOG.

#### **Outstanding properties:**

- competitive inhibitor of cGMP-dependent protein kinase type  $\mathbf{I}\alpha$ , based on the widely accepted 8-pCPT-cGMP
- totally resistant against all known mammalian cyclic nucleotide - dependent phosphodiesterases
- excellent membrane permeability due to high lipophilicity
- good solubility in aqueous media

Detailed technical information available, Cat. No.: C 013.



Forschungslabor und Biochemica - Vertrieb GmbH

Head office: Flughafendamm 9, P.O. Box 10 71 25 D-28071 Bremen, Germany Phone: 49 (0) 421 59 13 55 Fax: 49 (0) 421 59 47 71 US / Canada distributor: Ruth Langhorst Int'l. Marketing 7514 Girard Ave. Suite 1-411 La Jolla, CA 92037 Phone: (619) 457-1573 Fax: (619) 456-0810 In Japan contact: Wako Pure Chemical Ind., Ltd. Phone: Tokyo: 03-270-8571 0saka: 06-203-3741

#### Circle No. 10 on Readers' Service Card

## CUSTOM DNA

### SYNTHESIS

PURE & SIMPLE (and now more economical than ever)

PRIC	E \$	<b>7</b> .	<b>50</b>
+			per base plus setu

ш	20PEKR	TECHNICAL	SUPPORT
+			

IMPECCABLE (	QUALITY

П	WORLD'S	EACTECT	CEDVICE
ш	WOKLDS	LYOIEOI	OEK AICE

# **MIDLAND**

THE UNDISPUTED #1
CUSTOM DNA SYNTHESIS SERVICE

THE MIDLAND CERTIFIED REAGENT COMPANY 3112-A WEST CUTHBERT AVENUE MIDLAND, TEXAS, 79701

PHONE 1-800-247-8766

FAX 1-915-694-2387